Cytokinetics to Host Analyst & Investor Day on October 7, 2021
A panel discussion on the challenges of treating patients with heart failure with reduced ejection fraction (HFrEF) and the unmet need in this patient population will feature the following experts:
Tariq Ahmad , MD, MPH, FACC, Associate Professor of Medicine; Medical Director of Advanced Heart Failure, Cardiovascular Medicine,Yale School of Medicine Alanna Morris , MD, MSc, FHFSA, FACC, FAHA, Associate Professor of Medicine,Division of Cardiology ; Director ofHeart Failure Research ,Emory University Clinical Cardiovascular Research Institute
Interested parties must register online at https://bit.ly/3EGnmU3 by
About
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757
Source: Cytokinetics, Incorporated